76 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
5
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
Max Planck Institute For Developmental Biology
3
Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC).
Northwestern University
15
Innovative design and potential applications of covalent strategy in drug discovery.
Sichuan University
5
Modulating the Potency of BRD4 PROTACs at the Systems Level with Amine-Acid Coupling Reactions.
University of Michigan
8
Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα).
University of Michigan
8
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer.
University of Michigan
26
Heteroaryl Glutarimides and Dihydrouracils as Cereblon Ligand Scaffolds for Molecular Glue Degrader Discovery.
Genentech
43
Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) Kinase.
Bristol Myers Squibb
6
Recent advance of small-molecule drugs for clinical treatment of multiple myeloma.
Jilin University
7
Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9.
University of Michigan
4
Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivatives.
University of Bonn
14
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
University of Michigan
4
Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases.
The People's Hospital of Guangxi Zhuang Autonomous Region & Guangxi Academy of Medical Sciences
22
Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma.
Kymera Therapeutics
20
Discovery and characterization of potent spiro-isoxazole-based cereblon ligands with a novel binding mode.
Saint Petersburg State University
9
Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia.
Shenyang Pharmaceutical University
43
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.
Eberhard Karls University Tubingen
19
Facilitating the development of molecular glues: Opportunities from serendipity and rational design.
Sichuan University
3
Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy.
Sichuan University
29
Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity
University of Michigan
17
Development of sulfonyl fluoride chemical probes to advance the discovery of cereblon modulators.
Dana-Farber Cancer Institute
15
One-Pot Synthesis of Cereblon Proteolysis Targeting Chimeras via Photoinduced C(sp
Boehringer Ingelheim Rcv
17
Covalent Stapling of the Cereblon Sensor Loop Histidine Using Sulfur-Heterocycle Exchange.
Dana-Farber Cancer Institute
28
Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs.
University of Bonn
24
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer.
University of Michigan
30
Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines.
Saint Petersburg State University
3
Developments of PROTACs technology in immune-related diseases.
The Affiliated Hospital of Qingdao University
5
Discovery of Novel Bruton's Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy.
Stony Brook University
20
E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology.
AstraZeneca
14
Structural rationalization of GSPT1 and IKZF1 degradation by thalidomide molecular glue derivatives.
Dana-Farber Cancer Institute
10
A comprehensive review of BET-targeting PROTACs for cancer therapy.
Xinxiang Medical University
3
Developments of CRBN-based PROTACs as potential therapeutic agents.
The Affiliated Hospital of Qingdao University
12
Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation.
Second Military Medical University
12
Development of Potent and Selective Janus Kinase 2/3 Directing PG-PROTACs.
St. Jude Children'S Research Hospital
5
A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders.
Dana-Farber Cancer Institute
24
Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase.
AstraZeneca
21
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
Max Planck Institute For Developmental Biology
2
Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
Shaoxing University
7
Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
TBA
5
NOVEL INHIBITORS OF GUANOSINE MONOPHOSPHATE SYNTHETASE AS THERAPEUTIC AGENTS
University of Southern California
32
CDK12/13 COVALENT INHIBITORS OR PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
University of Michigan
63
SULFONYLPIPERAZINYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS
Hoffmann-La Roche
44
Disubstituted Pyrimidine Compounds for Ketohexokinase Inhibition
Centennial Therapeutics
130
ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF
1Cbio
196
Heterobicyclic compounds for inhibiting the activity of SHP2
Taiho Pharmaceutical
4
NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
Shanghai Hansoh Biomedical
13
Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
Novartis
10
Small molecule modulators of pantothenate kinases
St. Jude Children'S Research Hospital
31
Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
Prelude Therapeutics
2
Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase
Hanmi Pharm.